{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:23:45Z","timestamp":1764937425031},"reference-count":11,"publisher":"Walter de Gruyter GmbH","issue":"10","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This case follows a 54-year-old woman with a medical history of hypertension who experienced reactivation of minimal change disease (MCD) after receiving the Pfizer vaccine against COVID-19. She had her first episode of MCD 15\u00a0days after receiving the influenza vaccine in 2018. She remained in remission for over 3\u00a0years following treatment with steroids. She experienced foamy urine and leg edema after receiving the first dose of the Pfizer vaccine, but she did not consult medical professionals until she received the second dose. She wanted to be fully vaccinated because she worked in healthcare. Her initial diagnosis of MCD in 2018 was made following a kidney biopsy. The diagnosis of reactivation following COVID-19 vaccine was made with labs and presenting symptoms. At presentation, her urine protein was 9,977\u00a0mg\/day. She was treated with prednisone 50\u00a0mg\/day following her relapse with improvement in her urine protein to 85\u00a0mg\/g within 4\u00a0weeks of starting treatment. She is currently undergoing treatment with prednisone with improvement in her presenting symptoms, which included foaming of urine and edema of legs. This case demonstrates the importance of vigilance in patients with a history of MCD when receiving the COVID-19 vaccine, particularly if they have a history of such reactions to other vaccines. Patients should discuss the benefits and risks of receiving the vaccine with their medical professionals and stay cognizant about the possibility of reactivation after receiving the COVID-19 vaccine.<\/jats:p>","DOI":"10.1515\/jom-2022-0064","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T20:02:11Z","timestamp":1655236931000},"page":"499-501","source":"Crossref","is-referenced-by-count":6,"title":["Reactivation of minimal change disease after Pfizer vaccine against COVID-19"],"prefix":"10.1515","volume":"122","author":[{"given":"Sindhu","family":"Marampudi","sequence":"first","affiliation":[{"name":"Resident, Rowan School of Osteopathic Medicine Internal Medicine Residency , Stratford , NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafail","family":"Beshai","sequence":"additional","affiliation":[{"name":"Resident, Jefferson Health New Jersey Internal Medicine Residency , Stratford , NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopika","family":"Banker","sequence":"additional","affiliation":[{"name":"Nephrology and Hypertension Associates of New Jersey , Stratford , NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"2022092308092341860_j_jom-2022-0064_ref_001","doi-asserted-by":"crossref","unstructured":"Waldman, M, Crew, RJ, Valeri, A, Busch, J, Stokes, B, Markowitz, G, et al.. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007;2:445\u201353. https:\/\/doi.org\/10.2215\/CJN.03531006.","DOI":"10.2215\/CJN.03531006"},{"key":"2022092308092341860_j_jom-2022-0064_ref_002","doi-asserted-by":"crossref","unstructured":"Watts, AJB, Keller, KH, Lerner, G, Rosales, I, Collins, AB, Sekulic, M, et al.. Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol 2022;33:238\u201352. https:\/\/doi.org\/10.1681\/ASN.2021060794.","DOI":"10.1681\/ASN.2021060794"},{"key":"2022092308092341860_j_jom-2022-0064_ref_003","doi-asserted-by":"crossref","unstructured":"Vivarelli, M, Massella, L, Ruggiero, B, Emma, F. Minimal change disease. Clin J Am Soc Nephrol 2017;12:332\u201345. https:\/\/doi.org\/10.2215\/CJN.05000516.","DOI":"10.2215\/CJN.05000516"},{"key":"2022092308092341860_j_jom-2022-0064_ref_004","doi-asserted-by":"crossref","unstructured":"Lebedev, L, Sapojnikov, M, Wechsler, A, Varadi-Levi, R, Zamir, D, Tobar, A, et al.. Minimal change disease following the Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis 2021;78:142\u20135.","DOI":"10.1053\/j.ajkd.2021.03.010"},{"key":"2022092308092341860_j_jom-2022-0064_ref_005","doi-asserted-by":"crossref","unstructured":"Kutlucan, A, Gonen, I, Yildizhan, E, Aydin, Y, Sav, T, Yildirim, U. Can influenza H1N1 vaccination lead to the membranous glomerulonephritis? Indian J Pathol Microbiol 2012;55:239\u201341.","DOI":"10.4103\/0377-4929.97893"},{"key":"2022092308092341860_j_jom-2022-0064_ref_006","doi-asserted-by":"crossref","unstructured":"Patel, C, Shah, HH. Membranous nephropathy and severe acute kidney injury following influenza vaccination. Saudi J Kidney Dis Transpl 2015;26:1289\u201393. https:\/\/doi.org\/10.4103\/1319-2442.168676.","DOI":"10.4103\/1319-2442.168676"},{"key":"2022092308092341860_j_jom-2022-0064_ref_007","doi-asserted-by":"crossref","unstructured":"Lim, JH, Han, MH, Kim, YJ, Kim, MS, Jung, HY, Choi, JY, et al.. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: a case report and literature review. J Kor Med Sci 2021;36:e218. https:\/\/doi.org\/10.3346\/jkms.2021.36.e218.","DOI":"10.3346\/jkms.2021.36.e218"},{"key":"2022092308092341860_j_jom-2022-0064_ref_008","doi-asserted-by":"crossref","unstructured":"Leclerc, S, Royal, V, Lamarche, C, Laurin, LP. Minimal change disease with severe acute kidney injury following the Oxford-AstraZeneca COVID-19 vaccine: a case report. Am J Kidney Dis 2021;78:607\u201310. https:\/\/doi.org\/10.1053\/j.ajkd.2021.06.008.","DOI":"10.1053\/j.ajkd.2021.06.008"},{"key":"2022092308092341860_j_jom-2022-0064_ref_009","unstructured":"Remien, K, Vilella, RC. Osteopathic manipulative treatment: lymphatic procedures. Bethesda, MD: National Library of Medicine; 2021."},{"key":"2022092308092341860_j_jom-2022-0064_ref_010","unstructured":"Rivera-Martinez, S, Capobianco, JD. Osteopathic treatment of nephrotic syndrome. New York, NY: Osteopathic Medical Digital Repository; 2001."},{"key":"2022092308092341860_j_jom-2022-0064_ref_011","doi-asserted-by":"crossref","unstructured":"Hassanzadeh, S, Djamali, A, Mostafavi, L, Pezeshgi, A. Kidney complications following Covid-19 vaccination; a review of the literature. J Nephropharmacol 2021;11:e1. https:\/\/doi.org\/10.34172\/npj.2022.01.","DOI":"10.34172\/npj.2022.01"}],"container-title":["Journal of Osteopathic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jom-2022-0064\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jom-2022-0064\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T08:10:37Z","timestamp":1663920637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jom-2022-0064\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":11,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,6,17]]},"published-print":{"date-parts":[[2022,9,26]]}},"alternative-id":["10.1515\/jom-2022-0064"],"URL":"https:\/\/doi.org\/10.1515\/jom-2022-0064","relation":{},"ISSN":["2702-3648"],"issn-type":[{"value":"2702-3648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]}}}